证券代码：600736 证券简称：苏州高新 公告编号：2025-034 苏州新区高新技术产业股份有限公司 关于出售医疗器械产业公司47%股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 苏州新区高新技术产业股份有限公司（以下简称"公司"）拟向苏州高新区国有资本控股集团有限公司 （以下简称"苏高新国控"）出售苏州医疗器械产业发展集团有限公司（以下简称"医疗器械产业公司"） 47%股权，交易价格为60,444.14万元。 ● 本次交易不构成关联交易及重大资产重组，未达到股东会审议标准。 ● 截至本公告披露日，公司为医疗器械产业公司发行的公司债券24苏园01、25苏园01、25苏园02提供担 保，合计30,000万元。 一、交易概述 （一）本次交易的基本情况 1、本次交易概况 公司拟向苏高新国控出售医疗器械产业公司47%股权，交易价格为60,444.14万元。本次交易完成后，公 司对医疗器械产业公司的持股比例将由51.37%降至4.37%，不再将医疗器械产业公司纳入合并报表范 围。本次交易尚未签署协议。 ...

Core Viewpoint - Suzhou Gaoxin plans to sell a 47% stake in Suzhou Medical Device Industry Development Group for 604 million yuan, aiming to reduce the impact of the medical device company's underperformance on its financial statements [1][2]. Group 1: Transaction Details - The transaction price of 604 million yuan is based on an asset valuation report, reflecting a 12.93% premium over the book value of the stake [2]. - The payment will be made in installments, with 51% due by January 7, 2026, and the remaining 49% by March 31, 2026 [2]. - Suzhou Gaoxin's cost basis for the stake was 535 million yuan, indicating a transaction premium [2]. Group 2: Company Performance - Suzhou Medical Device Industry Development Group reported a revenue of 152 million yuan for 2024 and a net loss of approximately 81.81 million yuan [1]. - For the first three quarters of 2025, the company generated 140 million yuan in revenue with a net loss of about 101 million yuan [1]. Group 3: Strategic Implications - The sale is expected to enhance Suzhou Gaoxin's overall profitability by reducing the negative impact of the medical device company's performance on its financials [3]. - The company will continue to manage existing funds and projects while focusing on quality enterprises in the medical device sector and promoting green low-carbon industrial park operations [3].